Evaxion and undisclosed collaborator announce encouraging results for evx-b1 vaccine antigens against staphylococcus aureus infection

Copenhagen, denmark, april 02, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from evaxion's preclinical evx-b1 vaccine candidate against staphylococcus aureus (s. aureus). in the animal studies, the evx-b1 antigens significantly reduced disease burden. currently, the two companies are engaged in discussions regarding the path forward.
EVAX Ratings Summary
EVAX Quant Ranking